Regeneron’s chief executive, Dr. Leonard Schleifer, said the decision to make the new drug cocktail in the United States was both geopolitical and practical.
“You want to make it close to where the need is, and we anticipate there will be great need in the United States,” he said.
He acknowledged that making products overseas now posed risks that they could be subject to export bans in that country. In addition, Regeneron is receiving federal funds to expand its manufacturing of the vaccine, which carries the expectation that the company will prioritize the American market.
![[PukiWiki]](image/pukiwiki.png "[PukiWiki]")
